tumor-infiltrating lymphocyte therapy (Moffitt Cancer Center)

Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is an autologous cellular immunotherapy approach primarily utilized for treating solid tumors, particularly metastatic melanoma. The process begins with the surgical removal of a patient's tumor, from which naturally occurring T cells that have already recognized and infiltrated the malignancy are isolated. These TILs are expanded to large quantities ex vivo using high-dose interleukin-2 (IL-2). Following a non-myeloablative lymphodepleting chemotherapy regimen to eliminate suppressive immune cells, the expanded TILs are re-infused into the patient. Once back in the body, these polyclonal T cells target a broad spectrum of patient-specific neoantigens and tumor-associated antigens. In clinical research conducted at the Moffitt Cancer Center (e.g., NCT01701674), TIL therapy has been evaluated in combination with checkpoint inhibitors like ipilimumab to enhance clinical outcomes and prevent disease progression during the cell manufacturing period.

Other names

TIL therapyadoptive cell therapy with TILtumor-infiltrating lymphocytesACT with TILadoptive cell transfer with TIL